CN113677373A - RNAi分子 - Google Patents

RNAi分子 Download PDF

Info

Publication number
CN113677373A
CN113677373A CN202080023714.8A CN202080023714A CN113677373A CN 113677373 A CN113677373 A CN 113677373A CN 202080023714 A CN202080023714 A CN 202080023714A CN 113677373 A CN113677373 A CN 113677373A
Authority
CN
China
Prior art keywords
cancer
bcl
rnai molecule
nucleotides
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080023714.8A
Other languages
English (en)
Chinese (zh)
Inventor
田中洋行
高桥博一
高木义和
味吞宪二郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of CN113677373A publication Critical patent/CN113677373A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080023714.8A 2019-03-28 2020-03-26 RNAi分子 Pending CN113677373A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019064443 2019-03-28
JP2019-064443 2019-03-28
PCT/JP2020/013623 WO2020196736A1 (ja) 2019-03-28 2020-03-26 ＲＮＡｉ分子

Publications (1)

Publication Number Publication Date
CN113677373A true CN113677373A (zh) 2021-11-19

Family

ID=72611078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080023714.8A Pending CN113677373A (zh) 2019-03-28 2020-03-26 RNAi分子

Country Status (5)

Country Link
US (1) US20220170022A1 (https=)
EP (1) EP3950005A4 (https=)
JP (1) JPWO2020196736A1 (https=)
CN (1) CN113677373A (https=)
WO (1) WO2020196736A1 (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070969A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20060166920A1 (en) * 2005-12-27 2006-07-27 Regents Of The University Of Michigan Oligonucleotide based therapeutics
CN101522898A (zh) * 2006-06-26 2009-09-02 弗朗索瓦-巴克拉斯抗癌中心 使用Bcl-XL特异性siNA的癌症疗法
CN106177955A (zh) * 2016-08-18 2016-12-07 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN107075515A (zh) * 2013-11-22 2017-08-18 米纳治疗有限公司 C/EBPα组合物和使用方法
CN108064155A (zh) * 2014-12-26 2018-05-22 日东电工株式会社 用于p21基因调节的rna剂
CN113038956A (zh) * 2018-12-05 2021-06-25 日东电工株式会社 癌处置用RNAi分子

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0306148D0 (en) * 2003-03-18 2003-04-23 Milner Jo Regulation of gene expression
US20080261905A1 (en) 2004-11-08 2008-10-23 K.U. Leuven Research And Development Modified Nucleosides for Rna Interference
JP2019064443A (ja) 2017-09-29 2019-04-25 トヨタ紡織株式会社 乗物用シート

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
WO2003070969A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20060166920A1 (en) * 2005-12-27 2006-07-27 Regents Of The University Of Michigan Oligonucleotide based therapeutics
CN101522898A (zh) * 2006-06-26 2009-09-02 弗朗索瓦-巴克拉斯抗癌中心 使用Bcl-XL特异性siNA的癌症疗法
CN107075515A (zh) * 2013-11-22 2017-08-18 米纳治疗有限公司 C/EBPα组合物和使用方法
CN108064155A (zh) * 2014-12-26 2018-05-22 日东电工株式会社 用于p21基因调节的rna剂
CN106177955A (zh) * 2016-08-18 2016-12-07 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN113038956A (zh) * 2018-12-05 2021-06-25 日东电工株式会社 癌处置用RNAi分子

Also Published As

Publication number Publication date
EP3950005A1 (en) 2022-02-09
JPWO2020196736A1 (https=) 2020-10-01
US20220170022A1 (en) 2022-06-02
WO2020196736A1 (ja) 2020-10-01
EP3950005A4 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
JP7655971B2 (ja) ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP7039539B2 (ja) 乳酸デヒドロゲナーゼ及びその薬剤の治療的阻害
JP2022078069A (ja) 二本鎖ＲＮＡによるα－１アンチトリプシンの特異的阻害のための方法及び組成物
JP2023539341A (ja) Ｄｕｘ４阻害剤およびその使用方法
US20130023578A1 (en) siRNA for inhibition of c-Met expression and anticancer composition containing the same
US20240043837A1 (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
KR102701681B1 (ko) 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물
WO2015027895A1 (zh) 一种核酸和药物组合物及其应用
JP2022530678A (ja) 短縮センス鎖を有する二本鎖核酸阻害剤分子
AU2020289199B2 (en) Eph2A aptamer and uses thereof
CN113038956A (zh) 癌处置用RNAi分子
JPWO2006038608A1 (ja) オリゴ二本鎖ｒｎａ及び医薬組成物
CN113677373A (zh) RNAi分子
CN107709561B (zh) 修饰的siRNA及含有该修饰的siRNA的药物组合物
JP7208911B2 (ja) 核酸分子発現の調節
WO2023168202A2 (en) Certain dux4 inhibitors and methods of use thereof
CN119365601A (zh) 靶向RecQL1解旋酶基因的siRNA
WO2022081693A1 (en) Compositions and methods targeting circ2082 for the treatment of cancer
TW201718854A (zh) 供ｐ２１基因調控之ＲＮＡ干擾劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211119